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Patrix Metalloproteinases and Their
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uman Myocardium During Heart Failure Progression
ictoria Polyakova, PHD,* Stefan Hein, MD,† Sawa Kostin, MD,* Tibor Ziegelhoeffer, MD,*
utta Schaper, MD*
ad Nauheim, Germany
OBJECTIVES We studied the role of matrix metalloproteinases (MMPs) and their tissue inhibitors
(TIMPs) in fibrosis formation in the transition from hypertrophy to heart failure (HF) as well
as the cellular source of MMPs and TIMPs.
BACKGROUND Human pressure-overloaded hearts are characterized by a significant increase in cardiac
fibrosis. However, the contribution of the proteolytic/antiproteolytic system in aortic stenosis
(AS) during hypertrophy progression has not yet been elucidated.
METHODS Three groups of AS patients (I: EF50%, n 12; II: EF 50% to 30%, n 10; III: EF30%,
n 12) undergoing aortic valve replacement and seven controls were studied. Tissue samples were
investigated by immunoconfocal microscopy, Western blotting, and zymography.
RESULTS Quantitative analysis by immunoconfocal microscopy and Western blotting showed an
upregulation of MMP-1, -2, -3, -9, -13, and -14 in group I and further increases in later
stages. Tissue inhibitors of metalloproteinase-1 and -2 were enhanced and TIMP-4 was
decreased in comparison to control. Gelatinolytic activity of MMP-2 significantly (p  0.05)
increased 1.2-fold (group I), 1.5-fold (group II), and 1.6-fold (group III) over control. The
level of collagen I was significantly upregulated in all AS groups. Immunoconfocal microscopy
showed that MMPs and TIMPs are produced predominantly by fibroblasts. The number of
proliferating fibroblasts was significantly elevated during the transition to HF (0.67
n/mm2-control, 5.03-group III, p  0.05).
CONCLUSIONS In human hearts a continuous turnover of the extracellular matrix occurs during the
progression from compensated hypertrophy to HF that is characterized by the upregulation
of MMPs and inadequate inhibition by TIMPs. The altered balance between proteolysis/
antiproteolysis with accompanying proliferation of fibroblasts results in fibrosis
progression. (J Am Coll Cardiol 2004;44:1609–18) © 2004 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.023Cardiology Foundation
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secently, our group showed that in patients with hypertro-
hy due to aortic valve stenosis (AS) a continuous remod-
ling process of the left ventricular (LV) myocardium takes
lace and appears to be the major factor determining the
evelopment of heart failure (HF) (1). It was documented
hat a close correlation exists between cardiac function and
yocardial morphology and that the deterioration of clinical
V parameters occurred in parallel with progressive fibrosis,
yocyte degeneration, and cell death. However, the possi-
ility of an involvement of the enzymatic systems of
roteolysis and antiproteolysis in extracellular matrix
ECM) remodeling development has not been studied.
atrix metalloproteinases (MMPs) represent the major
roteolytic system for the ECM and, together with their
issue inhibitors (TIMPs), are of significant importance in
ardiac remodeling. The activity and expression of MMPs
nd TIMPs essentially vary in different cardiac diseases. In
xperimental hypertrophy the MMP portfolio has been
eported to be affected by diverse factors including the type
f cardiac overload (2). In human myocardium an MMP/
From the *Max-Planck-Institute and †Kerckhoff-Clinic, Bad Nauheim, Germany.
his work was supported by a grant from the Max-Planck Society.b
Manuscript received April 13, 2004; revised manuscript received June 17, 2004,
ccepted July 5, 2004.IMP imbalance was observed in end-stage HF (3,4),
hereas in experimental models a variable MMP expression
epending on the severity of hypertrophy was demonstrated
5–8). However, data about specific profiles of MMPs and
IMPs in AS during the transition from compensated to
ecompensated hypertrophy are missing.
Despite the fact that numerous reports demonstrate the
bility of different cell types to synthesize MMP in vitro
9,10), the cellular source of proteinases and their local
nhibitors in vivo is still an issue.
We hypothesized that fibrotic changes in the interstitium
f hypertrophied myocardium in AS patients are accompa-
ied by the consecutive development of an MMP/TIMP
mbalance and that mainly interstitial cells synthesize these
nzymes. The aim of the present research was two-fold: 1)
o evaluate the levels of MMPs and TIMPs in different
tages of hypertrophy and their involvement in ECM
emodeling; and 2) to determine the tissue source of these
roteolytic and antiproteolytic systems.
ATERIALS AND METHODS
atients. Thirty-four patients with isolated aortic valve
tenosis were subdivided into three different groups on the
asis of EF determined echographically at the time of
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MMPs and TIMPs in HF Progression October 19, 2004:1609–18dmission: I group, EF  50% (n  12); II group, EF 50%
o 30% (n  10); III group, EF  30% (n  12). All
atients had no evidence of any other cardiovascular disease
nd underwent surgical aortic valve replacement. Controls
onsisted of three donor hearts that were not used for
ransplantation and four biopsies from patients undergoing
losure of an atrial septum defect with normal left ventricles.
linical data are presented in Table 1. The institutional
thical Committee approved the study. All patients gave
nformed consent.
issue sampling. During open-heart surgery myectomy
amples of the LV subvalvular septum weighing about 30 to
0 mg were removed, immediately frozen in liquid nitrogen,
nd stored at 80°C. The tissue samples were mounted in
issue Tec and cryosections 5 m thick were prepared.
mmunolabeling and confocal microscopy. Cryosections
ere air dried and fixed for 10 min in acetone (20°C), 4%
ormalin, or Carnoys’ solution (room temperature). After
ashing in phosphate-buffered saline (PBS), sections were
ncubated with 1% bovine serum albumin for 30 min to
lock non-specific binding sites. After rinsing in PBS, the
amples were incubated in 4°C overnight with the primary
ntibodies (Table 2) MMP-1, -2, -3, -9, and -13, MT1-
MP, TIMP-1 and -2, cell proliferation associated protein
i67, vimentin, alpha-smooth muscle actin, CD31, CD68,
nd collagen I. Then sections were washed in PBS and
ncubated with secondary biotin-conjugated antibodies
anti-mouse and anti-sheep immunoglobulin G) for 1h
Abbreviations and Acronyms
AS  aortic stenosis
ECM  extracellular matrix
EF  ejection fraction
HF  heart failure
IHC  immunohistochemical
LV  left ventricular
MMP  matrix metalloproteinase
PBS  phosphate-buffered saline
TIMP  tissue inhibitor of metalloproteinase
WB  Western blot
able 1. Clinical Data
Control
Group
I
Group
II
Group
III
ge, yrs 58  6 70 6 67 12 71 7
en/women 3/4 5/7 5/5 7/5
F, % 61  8 59 8 41 5* 24 5*
VEDP, mm Hg 7  2 15  5 18 6* 32 8*
P mean, mm Hg 11  2 62 17 58 12 48 15
V mass/m2 102  12 137 26 131 57 156 34*
ortic valve area, cm2 0.9  0.3 0.6 0.3 0.6 0.2 0.5 0.2
iuretics, n 1 2 7 9
igitals, n 2 1 3 6
CE inhibitors, n 1 2 2 1
eta-blockers, n 2 3 4 3
p  0.05 vs. control. Data are expressed as mean  SEM or number of patients.t
ACE  angiotensin-converting enzyme; EF  ejection fraction; LVEDP  left
entricular end-diastolic pressure; LV  left ventricular.ollowed by incubation with Cy2 or Cy3 conjugated strepta-
idin. Nuclei were stained blue with TOTO3 (Molecular
robes, the Netherlands). Sections were embedded in
owiol and coverslipped. The samples were examined by
onfocal laser microscopy (Leica TCS-NT). Digital images
ere further processed for three-dimensional reconstruction
n a Silicon Graphics Octane Workstation using software
Imaris” and “Selima” (Bitplane, Zürich).
orphometry. Measurements of immunofluorescence
ere done with a Leica TCS-NT confocal microscope. For
uantitative analysis all sections were immunolabeled simul-
aneously using identical dilutions of primary and secondary
ntibodies and other reagents. Sections were scanned under
dentical parameters of imaging, zoom, pinholes, objectives,
nd laser power. Sections exposed to PBS instead of primary
ntibodies served as negative controls. One channel with the
ormat of 512  512 pixels and appropriate filters was used.
he confocal settings were standardized for all groups to
nsure that the image collected demonstrated a full range of
uorescence intensity from 0 to 255 pixel intensity level and
ere kept constant during all measurements. For each
atient at least 10 random fields of vision (size 150  150
m) were analyzed for the quantity of MMP and TIMP
sing images analysis software (Leica). The area occupied by
MPs, TIMPs or collagen I was calculated as percentage of
MP (TIMP or collagen I) labeling per tissue area. In the
uantification of fibrosis only interstitial fibrosis was
ncluded.
uantification of Ki-67-positive fibroblasts. The num-
er of proliferating fibroblasts was determined at a micro-
copic magnification of X250 from at least five different
andomly chosen fields of sections stained for Ki-67, vimen-
able 2. Primary Antibodies
Antibody Type Clone Company
MP-1 Mono- Collagenase 1 Calbiochem, Oncogene
MP-1 Poly- Collagenase 1 Biotrend
MP-2 Mono- Gelatinase A Oncogene
MP-2 Poly- Gelatinase A Biotrend
MP-3 Mono- Stromelysin 1 Oncogene
MP-3 Poly- Stromelysin 1 Biotrend
MP-9 Mono- Gelatinase B Calbiochem, Oncogene
MP-9 Poly- Gelatinase B Biotrend
MP-13 Mono- Collagenase 3 Oncogene
MP-13 Poly- Collagenase 3 Biotrend
T1-MMP Mono- MMP 14 Calbiochem, Oncogene
IMP-1 Mono- — Calbiochem
IMP-2 Mono- — Calbiochem
IMP-4 Mono- — Sigma
lpha-smooth
muscle actin
Mono- 1A4 Sigma
lpha-actin Mono- HHF 35 Sigma
imentin Mono- V9 Sigma
D31 Mono- JCI 70 A DAKO
D68 Mono- EBM11 DAKO
ollagen I Mono- COL-1 Sigma
i67 Mono- MIB-1 DAKO
MP  matrix metalloproteinase; TIMP  tissue inhibitors of metalloproteinase.in, and TOTO3 and calculated as n/mm2.
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October 19, 2004:1609–18 MMPs and TIMPs in HF Progressionymography. Zymography was done according to a well-
escribed protocol (6). In brief, LV samples were homog-
nized in ice-cold extraction buffer and centrifuged at 8,000
for 30 min at 4°C. Proteins were determined by Bradford
ssay. The myocardial extracts were loaded onto electro-
horetic gels (SDS-PAGE) containing a gelatin (0.1%) or
asein (0.1%) substrate under non-reducing conditions.
fter electrophoresis the gel was incubated twice in rena-
urating buffer for 30 min each (25°C), rinsed in water, and
ncubated for 20 h in developing buffer (25°C). Samples
ere incubated in the presence of 1 mM of phenylmethyl-
ulphonylfluoride (inhibitor of serine proteinase) and 5 mM
odacetamide (inhibitor of cysteine protease). To study
nhibition of the enzymes, an identical gel was incubated in
eaction buffer containing 20 mM ethylene-diaminetetraacetic
igure 1. Expression and quantitative analysis of matrix metalloprotein
icrographs showing typical staining patterns of MMPs, an example is M
ote that in the control myocardium, MMP-1 is localized mainly in the
hereas diseased myocardium showed larger areas of MMP-1. Nuclei are s
nd TIMPs are expressed as percent increase in aortic stenosis groups com
ncreased with hypertrophy progression.cid, an inhibitor of MMPs. After the reaction, the gel was ctained with 0.25% Commassie brilliant blue R 250. Zones
f lysis were visualized as clear bands against the blue
ackground. To test the linearity of zymographic activity
ifferent concentrations of proteins were used.
The zymograms were digitized using constant light in-
ensity. The size of bands indicating MMP activity was
etermined by quantitative image analysis.
estern blot. Frozen tissue was homogenized in lysis
uffer and centrifuged for 10 min. Left ventricular myocar-
ial extracts were loaded onto 4% to 12% polyacrylamide gel
nd separated under reducing conditions. Proteins were
lectrotransferred onto nitrocellulose membrane (Invitro-
en) and blocked with 5% non-fat dry milk in Tris-buffered
aline Tween-20 (TBST) at 4°C. After washing with
BST, proteins were exposed overnight at 4°C to mono-
MMPs) and tissue inhibitors of metalloproteinase (TIMPs). Confocal
fluorescence (green) in control (A) and diseased myocardium (B and C).
stitial cells and signal occupies restricted areas of the extracellular matrix
blue with TOTO3. (D) Quantitative immunofluorescent data of MMPs
to controls. All analyzed MMPs and TIMPs demonstrate a trend to beases (
MP-1
inter
tained
paredlonal antibodies (Table 2) against MMP-1, -2, -3, and -9,
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MMPs and TIMPs in HF Progression October 19, 2004:1609–18IMP-4 (1 mg/ml), MMP-13, MT1-MMP, TIMP-1 and
2 (2 mg/ml) diluted in TBS with 5% powdered milk.
ound antibodies were detected by peroxidase-conjugated
uman anti-mouse or anti-rabbit immunoglobulin G horse-
adish peroxidase-conjugated and SuperSignal WestFemto
Pierce) detection system and exposed to X-ray film. In
rder to equalize data, immunoblotting for sarcomeric
lpha-actin was performed and all specific values of proteins
ere standardized to sarcomeric actin.
Quantification of immunoblots and zymograms was done
y scanning on a STORM 860 (Amersham Pharmacia
iotech) using ImageQuant software.
tatistical analysis. All data are presented as means 
EM. Differences by parametric analysis of variance fol-
owed by Bonferroni’s multiple comparison test or nonpara-
etric Kruskal-Wellis with Dunn’s post-test were consid-
red significant at p  0.05.
ESULTS
MPs (TIMPs) staining patterns. Matrix metallopro-
einases and TIMPs showed similar staining patterns within
he ventricular myocardium with heterogeneous degrees of
xpression. We observed specific immunofluorescence label-
ng in some interstitial cells (Fig. 1A), multilocal or diffuse
mmunoreactivity in the perivascular areas (Fig. 1B), and
ultilocal or diffuse staining in fibrotic regions (Fig. 1C).
MPs’ zymographic activity. Proteolytic activity of
MPs was detected in all tissues by zymography. Clear
igure 2. Representative gelatin zymography and quantitative analysis. Ge
ymographic activity of matrix metalloproteinase-2 is significantly enhancands represent gelatinolytic activity of MMP-9, pro- mMP-2, and MMP-2 (Fig. 2). The zymography revealed
hat the majority of the detected activity could be
ttributed to MMP-2, which is significantly increased in
atients with AS. We found that zymographic activity
as linear with respect to protein content in both control
nd AS samples. The levels of MMP-3 and -13 were
ssessed by casein zymography, but no EDTA-sensitive
ands were found.
MP expression. All MMPs demonstrated a tendency to
e upregulated already in group I and the upregulation further
ncreased with the progression of hypertrophic changes (Figs.
A to 3F). Data obtained from quantitative immunohisto-
hemical (IHC) analysis were in agreement with Western blot
WB) findings but not identical, most probably because of
ifferences in methodical approaches. MMP-1 IHC expres-
ion significantly increased in all AS groups in comparison with
ontrol (Fig. 1D), whereas by WB, MMP-1 was significantly
nhanced only in group III (Fig. 3A). The other collagenase,
MP-13, which normally is totally absent or present
n scanty amounts in normal heart (10), was conspicuously
levated in diseased myocardium (Figs. 1D and 3C). Matrix
etalloproteinase-3 abundance was significantly upregulated
n severe hypertrophy in both IHC and WB analysis (Figs. 1D
nd 3B). The MT1-MMP protein content was enhanced in all
S groups, whereas IHC showed an insignificant increase only
n group I as compared to control. Matrix metalloproteinase-2
as enhanced with the transition to HF (Figs. 1D and 3E)
hat correlated with its gelatinolytic activity (Fig. 2). In con-
rast, the elevation of MMP-9 protein (Fig. 3F) was not
lytic activities were identified as clear bands against the dark background.
aortic stenosis patients as compared with control.atched by an increased activity (Fig. 2).
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October 19, 2004:1609–18 MMPs and TIMPs in HF ProgressionIMP expression. Increased expression of TIMP-1 and -2
n decompensated hypertrophy was demonstrated by both
HC and WB (Figs. 1D, 3G, and 3H). Nevertheless, the IHC
mount of TIMP-1 was rather poor in comparison with
yocardial ECM collagen I and MMP-1, even in group III
ith the highest tissue content of this inhibitor (Figs. 4A to
C). At the same time the abundance of TIMP-4 observed in
ontrols tended to be decreased in the hypertrophy groups I
nd III and was significantly depressed in group II (Fig. 3I).
ibrosis. The level of collagen I was upregulated in all
roups of AS patients as compared with control. Myocardial
brosis significantly increased with the transition to HF
Fig. 4D).
issue source of MMP (TIMP) production. To deter-
ine the tissue source of MMP (TIMP), we used both
ouble sequential immunolabeling and serial sections. Im-
unohistochemical analysis showed that the contribution of
ndothelial cells (Figs. 5A and 5B) as well as smooth muscle
ells (Figs. 5C and 5D) in the secretion of MMPs is rather
egligible. In contrast, double staining for MMPs and
imentin demonstrated that the majority of cells in the
MP-containing area were fibroblasts (Figs. 6A to 6D).
etween fibroblasts we found a few macrophages (Fig. 6D)
hat were often in close contact with fibroblasts (data not
igure 3. Representative Western blots and quantitative results of MMPs
hown in panel C) during the transition from compensated hypertrophy thown) and most likely take part in fibroblast activation. purprisingly, we found that fibroblasts are producing not
nly matrix proteinases but also their tissue inhibitors
TIMP-1, -2, and -4), of which TIMP-1 is shown as an
xample (Figs. 6E and 6F).
As previously reported, in hypertrophied myocardium
nly a few inflammatory cells were present. Therefore, their
articipation in MMP (TIMP) synthesis is least of all
robable or insignificant. In cardiomyocytes occurrence of
MP (TIMP) was not found.
i-67 associated antigen and myofibroblasts. Prolifera-
ion of myocardial fibroblasts was a rare event in the control
roup, whereas in patients of group III the number of
i-67-positive fibroblasts was increased 7.5-fold (Figs. 7A
nd 7B). In addition, in patients with decompensated
ypertrophy we observed myofibroblasts (Figs. 7C and 7D).
ISCUSSION
everal studies have reported a selective increase of MMP
nd TIMP levels and MMP activity in myocardium of
atients with end-stage HF in both non-ischemic and
schemic cardiomyopathies (11).
he present study. The novel observation of the present
tudy is a characterization of different MMP and TIMP
F) and TIMPs (G to I) expression normalized to actin content (42 kDa,
rt failure. Abbreviations as in Figure 1.rofiles in patients with AS depending on the degree of
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MMPs and TIMPs in HF Progression October 19, 2004:1609–18ypertrophy. We demonstrate that in AS the amount and
istribution of both MMPs and their inhibitors are involved
n the remodeling of myocardium in different stages of
ypertrophy. Matrix metalloproteinases and TIMPs were
ituated in the ECM and mainly colocalized with fibrosis.
n normal human myocardium, the protein content of
MPs was comparatively low. In failing myocardium, all
MPs studied here were significantly or insignificantly
pregulated and correlated with the degree of fibrosis and
ypertrophy. Interestingly, almost all MMPs had sharply
ncreased already in group I, where fibrosis is already
levated but cardiac EF is still normal. Similarly, TIMP-1
nd -2 were low in control tissue, increased (TIMP-2) or
ended to be upregulated (TIMP-1) in compensated hyper-
rophy (group I), and were highest in failing hearts (group
I, III), whereas TIMP-4 demonstrated a tendency to be
ower in all AS groups than in controls. It is evident that the
yocardial ECM in AS is in a highly dynamic state and
aries depending on the degree of hypertrophy progression.
hanges in MMP and TIMP expression can serve as early
arkers of remodeling in pressure-overloaded myocardium.
In our previous study the level of fibronectin (one of the
arkers of fibrosis) was shown to be increased in the ECM
f myocardium in patients with AS (1). We documented a
igure 4. Immunostaining (serial sections) for collagen I (A), MMP-1 (B)
emonstrating that the amount of TIMP-1 is obviously less in comparison w
uclei are blue. (D) Quantitative analysis of collagen I per tissue area demo
ypertrophy. Abbreviations as in Figure 1.egative correlation between EF and fibrosis and showed ehat patients with the highest level of fibrosis (group III)
ere characterized by incomplete postoperative recovery. In
ur present work we measured the level of collagen I, the
arker of mature fibrosis and the main substrate of MMP-1
nd other MMPs. The degree of fibrotic changes correlated
ith upregulation of MMPs, TIMP-1 and -2, and the
ecrease of TIMP-4. That indicates the contribution of
hese enzymes to the remodeling of ECM and the clinical
evelopment of HF.
tudy limitations. Because for ethical reasons the removal
f repetitive biopsies was not possible, we subdivided the
atients in representative groups. Repeated clinical studies
f these AS patients confirmed the strong relationship of
unctional/structural characteristics that led us to interpret
hanges in groups with different EF as certain stages of
ypertrophy progression.
Taking into account the possible interference of turbu-
ence on tissue structure and composition of myoectomies,
he innermost endocardial part of the samples was not
nalyzed. Several samples of LV free wall were studied for
he purpose of MMP and TIMP expression. The findings
ere similar to the current data, but myoectomies were
urther analyzed because they are easier for surgical and
TIMP-1 (C) in myocardium of patients with the lowest ejection fraction
ollagen I and MMP-1. Collagen I is red, MMP-1 and TIMP-1 are green,
tes significantly increased levels of fibrosis in patients with decompensated, and
ith c
nstrathical reasons to obtain.
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October 19, 2004:1609–18 MMPs and TIMPs in HF Progressionissue source of MMPs and TIMPs. Myocardial MMPs
re produced by a variety of cells such as fibroblast-like cells,
ascular smooth muscle cells, endothelial cells, infiltrating
nflammatory cells and by cardiomyocytes (9,10,12–14).
oreover, according to numerous recent reports, practically
ll parenchymal and mesenchymal cells are able to synthe-
ize extracellular proteinases. At the same time, there are
nly few data concerning the cellular origin of TIMPs (15).
owever, the overwhelming majority of investigations were
one in vitro and the data cannot be completely extrapolated
o the situation in vivo (16). In this study we have shown
hat the main cellular sources of MMPs and TIMPs in
yocardium of AS patients are fibroblasts and that the
ontribution of other cells is negligible.
he role of fibroblasts in ECM remodeling. About 90%
f the myocardial ECM cells are fibroblasts. Nevertheless,
e found an increased number of proliferating fibroblasts in
ecompensated hypertrophy, likely because of intensive
emodeling of the ECM. It has been illustrated in several
eports that fibroblasts are a rather heterogeneous popula-
ion that preserves its heterogeneity in vitro, demonstrating
ifferent responses to some cytokines (17,18). In the myo-
ardial ECM of patients with progressing hypertrophy, we
bserved by electron microscopy the presence of fibroblasts
haracterized by diverse size and shape with different
igure 5. Immunostaining (serial sections) for MMP-9 (A), CD31 and vim
bsence of colocalization of MMPs in both endothelial cells and smooth m
re green; vimentin is red; and nuclei are blue. Abbreviations as in Figurumbers of subcellular organelles and varying nuclear con- fguration (data not shown) and myofibroblasts. It remains
nknown whether different matrix proteins including
MPs and TIMPs are synthesized by the same fibroblasts
r whether there are different subpopulations of fibroblasts
ith limited functional specialization. Until now it has been
stablished only that myofibroblasts have the capacity to
roduce both structural ECM proteins and proteinases (19).
t is probable that a number of neurohormonal and cytokine
ignaling cascades determine the myocardial MMP and
IMP expression and activity in different cardiovascular
isease states. Future studies are necessary to investigate the
switching over” phenomenon of cardiac fibroblasts and the
actors involved in determining their synthetic specificity.
his may represent a promising therapeutic target.
he paradox of the study. Collagen accumulation increased
ith the progression of hypertrophic changes in spite of
nhanced MMP levels. Augmentation of MMP expression
nd activity in failing human myocardium was accompanied by
n increase of TIMP-1 and -2 that would imply reduced
MP activity. This is at first sight a paradox, but it may be a
atural phenomenon as long as MMPs not only degrade
atrix components but also modulate collagen synthesis. It is
ot clear which event is initial, reactive fibrosis or MMP
ctivation, as they both were present already in patients with
ompensated hypertrophy and can be provoked by the same
(B), MMP-1 (C), alpha-smooth muscle actin and vimentin (D) showing
cells. Matrix metalloproteinases, endothelial cells, and smooth muscle cellsentin
uscleactors. In a previous study we revealed a significant upregula-
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MMPs and TIMPs in HF Progression October 19, 2004:1609–18ion of transforming growth factor-beta and angiotensin-
onverting enzyme inhibitors in AS patients (1). Their local-
zation and concentration-dependent release may favor the
mbalance between degradation and synthesis of ECM pro-
eins with a prevalence of fibrotic changes. On the other hand,
his discordance can be caused by insufficient inhibitory control
f hypertrophy progression. In normal myocardium the cleav-
ge of ECM proteins by MMPs is strictly limited and ECM
s characterized by the presence of native “undenaturated”
nterstitial proteins including collagen. Upregulation of MMPs
t different levels of hypertrophy suggests an insufficiency of the
igure 6. Cellular sources of MMP and TIMP (A to F). Double labeling f
ajority of cells in the MMP occupied area. Serial sections stained for MM
n the MMP containing regions are fibroblasts and only a few macrophag
xample) (green) (E) and vimentin (red) (F) demonstrating fibroblasts innhibitory mechanism. It is known that TIMP-2, on one hand, Ms able to specifically inhibit MMP-2 but, on the other
and, to promote its activation (20). Tissue inhibitor of
etalloproteinase-1 inhibits most of the known MMPs by
orming complexes in a stoichiometric ratio of 1:1 although
t poorly inhibits membrane-type MMPs and MMP-19
20,21). Data from IHC analysis revealed a very low tissue
ontent of TIMP-1 relative to the elevated levels of
MP-1 and the magnitude of fibrotic changes (Figs. 6A to
C). Therefore, the observed elevation of TIMP-1 and -2
rotein levels may not necessarily translate into reduced
MP activity because in failing human LV the amount of
MP-1 (green) (A) and vimentin (red) (B) showing that fibroblasts are the
green) (C) and vimentin (red), CD68 (green) (D). Note: most of the cells
e present (arrows). Sequential staining for TIMP (TIMP-1 shown as an
P-positive areas. Nuclei are blue. Abbreviations as in Figure 1.or M
P-2 (
es arMP/TIMP complexes can be decreased while the ratio of
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October 19, 2004:1609–18 MMPs and TIMPs in HF Progressionree to bound TIMP will increase (11). In addition, gelati-
ases can be activated by stromelysin MMP-3 even in the
resence of TIMPs (22). Tissue inhibitor of metallo-
roteinase-4 is the most cardiospecific among the known
nhibitors of MMPs and possesses a higher inhibitory
otential than the other TIMPs (23). In the present study,
IMP-4 was found to be repressed, which is in agreement
ith other reports (3,24,25). A decreased level of this
nhibitor testifies to weakening of its cardioprotective abil-
ties against an elevated MMP background and is presum-
bly a decisive factor in HF progression. In hypertrophied
yocardium, an insufficient increase or lack of stimulation
f TIMPs fails to supply the necessary control of upregu-
ated MMPs that is accompanied by accumulation of
abnormal” collagen and other extracellular components. Li
t al. (26) consider that matrikines, side products of MMP
ctivity, stimulate fibrosis progression.
It is also very probable that fibroblasts are the main affected
ink in the chain of stoichiometric MMP/TIMP imbalance
evelopment. Cardiac fibroblasts represent a heterogeneous
opulation, which is able to produce ECM proteins as well as
roteolytic and antiproteolytic agents. The stimulation of
broblasts by profibrotic cytokines such as TGF-beta and
ngiotensin-converting enzyme inhibitors might override any
igure 7. Proliferating fibroblasts and presence of myofibroblasts in patient
ntigen-Ki67 (green) is confined to fibroblasts labeled for vimentin (red
arrows) in the myocardial ECM expressing alpha-smooth muscle actin (grrotein degradation effects of MMPs. The net result of thectivity of profibrotic and antifibrotic influences is a significant
nd continuously increasing degree of fibrosis.
onclusions. In human hearts the progression from com-
ensated hypertrophy to HF is accompanied by altered MMP
nd TIMP levels. Cardiac fibroblasts proliferate and take an
ctive part in ECM remodeling during hypertrophy progres-
ion. In AS the upregulation of MMPs and inadequate
nhibition by TIMPs occur in an early stage and continue in
urther stages of hypertrophy that finally contribute to a high
egree of fibrosis and reduction of cardiac function.
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